To access the therapeutic roles of anti-cytokine mAb in vivo, we inoculated 5-day-old neonatal mice via i.m. with 104 TCID50 CVA2 and administered with isotype control, anti-TNF-α, anti-IL-6, and anti-MCP-1 mAbs via the i.p. route at 12 h post infection. This evidence concerns the gene IL6 and infection.